Sugi Predict

Sugi Predict / Compounds / Gedocarnil

Gedocarnil

Gedocarnil

SCHEMBL194687

COCc1c(C(=O)OC(C)C)ncc2[nH]c3cccc(Oc4ccc(Cl)cc4)c3c12

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 17/20 0.59
▸ GABRG2 P18507 17/20 0.59
▸ GABRB3 P28472 17/20 0.59
▸ GABRA5 P31644 17/20 0.59
▸ GABRA3 P34903 17/20 0.59
▸ GABRA2 P47869 15/20 0.59
▸ GABRP O00591 11/20 0.59
▸ GABRD O14764 11/20 0.59
▸ GABRB1 P18505 11/20 0.59
▸ GABRB2 P47870 11/20 0.59
▸ GABRA4 P48169 11/20 0.59
▸ GABRE P78334 11/20 0.59
▸ GABRA6 Q16445 11/20 0.59
▸ GABRG1 Q8N1C3 11/20 0.59
▸ GABRG3 Q99928 11/20 0.59
▸ GABRQ Q9UN88 11/20 0.59
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gedocarnil SCHEMBL29388645 1.00 GABRA1 (0.59) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9533643 0.92 GABRA1 (0.62) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10389601 0.91 GABRA1 (0.57) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10390481 0.91 GABRA1 (0.59) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9689355 0.90 GABRA1 (0.57) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL8845928 0.89 GABRA1 (0.66) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10417007 0.89 GABRA1 (0.58) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9537306 0.88 GABRA1 (0.70) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9538117 0.88 GABRA1 (0.60) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL8475965 0.88 GABRA1 (0.56) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022086835-A1 COMBINATION PRODUCTS TO MITIGATE THE RISK OF NON-BENZODIAZEPINE BENZODIAZEPINE AGONIST ADVERSE REACTION AND OVERDOSE PRESTI MICHAEL (US) 2022-04-28 — — WO claimed
US-20220117916-A1 Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose SAFERX PHARMACEUTICALS LLC (US) 2022-04-21 — — US claimed
WO-2015072853-A1 TREATMENT OF HERPES VIRUS INFECTION OUTBREAKS RJG DEVELOPMENTS B.V. (NL) 2015-05-21 — — WO claimed
WO-2015072852-A1 TREATMENT OF HERPES VIRUS INFECTION OUTBREAKS USING VALERIAN RJG DEVELOPMENTS B.V. (NL) 2015-05-21 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20060292202-A1 Drug delivery device BAUSCH & LOMB INCORPORATED 2006-12-28 — — US claimed
EP-0234173-B1 PHENOXY-SUBSTITUTED BETA-CARBOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 1993-06-16 — — EP claimed
US-4945090-A ANXIOLYTIC AGENTS, ANTICONVULSANTS SCHERING AKTIENGESELLSCHAFT (DE) 1990-07-31 — — US claimed
US-12318359-B2 Combination methods and compositions including sleep therapeutics for treating mood FEUERSTEIN SETH (US) 2025-06-03 — — US disclosed
US-20250163130-A1 LIGAND GATED ION CHANNELS AND METHODS OF USE SWITCH BIO, INC. 2025-05-22 — — US disclosed
US-20250152742-A1 COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES TRAMES BIO, INC. 2025-05-15 — — US disclosed
US-20030045541-A1 GABA-Receptor modulators with NMDA-Antagonistic activity SCHERING AKTIENGESELLSCHAFT (DE) 2003-03-06 — — US disclosed
WO-2002078680-A1 GABA-RECEPTOR MODULATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OF THE EYE DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH (DE) 2002-10-10 — — WO disclosed
US-5569661-A Process for the production of b-carbolines SCHERING AKTIENGESELLSCHAFT (DE) 1996-10-29 — — US disclosed
US-4945090-A ANXIOLYTIC AGENTS, ANTICONVULSANTS SCHERING AKTIENGESELLSCHAFT (DE) 1990-07-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045541-A1 GABA-Receptor modulators with NMDA-Antagonistic activity GRIN2A, GRIN1, GABRD GABRA1 4/4885GABRG2 19/4885GABRB3 16/4885
US-20250152742-A1 COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES CHRNB2, CHRNA2, CHRNA6 GABRA1 138/4885GABRG2 104/4885GABRB3 98/4885
US-20250163130-A1 LIGAND GATED ION CHANNELS AND METHODS OF USE CACNB2, CHRNA2, HCN3 GABRA1 175/4885GABRG2 148/4885GABRB3 144/4885
US-20060292202-A1 Drug delivery device ALDH1A2, ADRB2, ADRA2B GABRA1 1125/4885GABRG2 1494/4885GABRB3 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.